Celldex Therapeutics Past Earnings Performance
Past criteria checks 0/6
Celldex Therapeutics's earnings have been declining at an average annual rate of -25.5%, while the Biotechs industry saw earnings growing at 15.5% annually. Revenues have been declining at an average rate of 5.8% per year.
Key information
-25.5%
Earnings growth rate
8.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -5.8% |
Return on equity | -17.3% |
Net Margin | -2,386.0% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns
Jun 07We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jun 05We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth
Jul 07An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued
Apr 21Companies Like Celldex Therapeutics (NASDAQ:CLDX) Are In A Position To Invest In Growth
Feb 27We're Not Very Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Rate
Sep 07Celldex begins dosing in mid-stage study of barzolvolimab for skin disorder
Jul 21Celldex: Barzolvolimab Plus Bispecific Antibodies Advancement
Jul 14Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans
May 25Are Investors Undervaluing Celldex Therapeutics, Inc. (NASDAQ:CLDX) By 31%?
Feb 03Celldex: Pipeline Of Drug Candidates Is Worth A Look
Feb 01Celldex Therapeutics: A Best Price-Positioned Biotech Stock As Seen By Market-Makers
Sep 23We Think Celldex Therapeutics (NASDAQ:CLDX) Can Easily Afford To Drive Business Growth
Sep 15Celldex: Powerful Medicines To Yield Further Upsides
Jul 08Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation
May 12We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely
Jan 27Revenue & Expenses Breakdown
How Celldex Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 6 | -145 | 33 | 0 |
31 Dec 23 | 7 | -141 | 31 | 0 |
30 Sep 23 | 4 | -125 | 29 | 0 |
30 Jun 23 | 3 | -113 | 27 | 0 |
31 Mar 23 | 3 | -119 | 27 | 0 |
31 Dec 22 | 2 | -112 | 27 | 0 |
30 Sep 22 | 1 | -106 | 27 | 0 |
30 Jun 22 | 1 | -100 | 26 | 0 |
31 Mar 22 | 4 | -77 | 23 | 0 |
31 Dec 21 | 5 | -71 | 20 | 0 |
30 Sep 21 | 8 | -72 | 18 | 0 |
30 Jun 21 | 9 | -66 | 16 | 0 |
31 Mar 21 | 5 | -64 | 15 | 0 |
31 Dec 20 | 7 | -60 | 14 | 0 |
30 Sep 20 | 5 | -48 | 14 | 0 |
30 Jun 20 | 4 | -46 | 14 | 0 |
31 Mar 20 | 5 | -46 | 14 | 0 |
31 Dec 19 | 4 | -51 | 15 | 0 |
30 Sep 19 | 4 | -50 | 17 | 0 |
30 Jun 19 | 5 | -46 | 17 | 0 |
31 Mar 19 | 7 | -50 | 19 | 0 |
31 Dec 18 | 10 | -151 | 19 | 0 |
30 Sep 18 | 11 | -146 | 21 | 0 |
30 Jun 18 | 14 | -165 | 22 | 0 |
31 Mar 18 | 15 | -177 | 23 | 0 |
31 Dec 17 | 13 | -93 | 25 | 0 |
30 Sep 17 | 11 | -121 | 27 | 0 |
30 Jun 17 | 9 | -125 | 29 | 0 |
31 Mar 17 | 7 | -128 | 30 | 0 |
31 Dec 16 | 7 | -129 | 34 | 0 |
30 Sep 16 | 7 | -129 | 35 | 0 |
30 Jun 16 | 6 | -131 | 37 | 0 |
31 Mar 16 | 6 | -132 | 37 | 0 |
31 Dec 15 | 5 | -127 | 34 | 0 |
30 Sep 15 | 5 | -126 | 29 | 0 |
30 Jun 15 | 5 | -122 | 26 | 0 |
31 Mar 15 | 4 | -118 | 22 | 0 |
31 Dec 14 | 4 | -118 | 21 | 0 |
30 Sep 14 | 3 | -108 | 19 | 0 |
30 Jun 14 | 3 | -103 | 18 | 0 |
31 Mar 14 | 2 | -94 | 16 | 0 |
31 Dec 13 | 4 | -82 | 15 | 0 |
30 Sep 13 | 7 | -76 | 13 | 0 |
30 Jun 13 | 9 | -68 | 12 | 0 |
Quality Earnings: CLDX is currently unprofitable.
Growing Profit Margin: CLDX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLDX is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.
Accelerating Growth: Unable to compare CLDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: CLDX has a negative Return on Equity (-17.28%), as it is currently unprofitable.